株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

低分子ヘパリン(LMWH)の世界市場:医薬品タイプ別(エノキサパリン、ダルテパリン、チンザパリン)、用途、流通経路別 - 産業洞察、動向、見通し、市場機会の分析2017年~2025年

Low Molecular Weight Heparin Market - by Drug Type (Enoxaparin, Dalteparin, Tinzaparin, & Others), Application, & Distribution Channel - Global Industry Insights, Trends, Outlook, & Opportunity Analysis 2017-2025

発行 Coherent Market Insights 商品コード 833118
出版日 ページ情報 英文 218 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
低分子ヘパリン(LMWH)の世界市場:医薬品タイプ別(エノキサパリン、ダルテパリン、チンザパリン)、用途、流通経路別 - 産業洞察、動向、見通し、市場機会の分析2017年~2025年 Low Molecular Weight Heparin Market - by Drug Type (Enoxaparin, Dalteparin, Tinzaparin, & Others), Application, & Distribution Channel - Global Industry Insights, Trends, Outlook, & Opportunity Analysis 2017-2025
出版日: 2019年04月16日 ページ情報: 英文 218 Pages
概要

低分子ヘパリン(LMWH)は未分化ヘパリン(UFH)と比較し活性期間の長さや予測性の面でより優れているほか、在宅環境下でも自己皮下注射を行うことができ、定期的な血液検査を必要としません。また、ヘパリンは胎盤を通過せず胎児への影響もないことから、凝固剤として血栓症の高リスク患者や妊婦に利用されています。

当レポートでは、世界の低分子ヘパリン市場を調査し、市場の概要、医薬品・包装・用途・エンドユーザー・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場概要

  • レポート概要
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場スニペット:医薬品別
    • 市場スニペット:包装別
    • 市場スニペット:用途別
    • 市場スニペット:エンドユーザー別
    • 市場スニペット:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場力学、規制、動向分析

  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会
  • 影響分析
  • 疫学
  • 主な開発動向
  • 戦略的買収
  • LMWHの利点 - 対UFH比
  • LMWHとUFHの費用対効果
  • エノキサパリン不足と推定補給日
  • ドラッグデリバリーシステム
  • 規制シナリオ
  • 返済シナリオ
  • PEST分析

第4章 世界の低分子ヘパリン市場:医薬品別

  • イントロダクション
  • エノキサパリン
  • ダルテパリン
  • ナドロパリン
  • ベミパリン
  • チンザパリン
  • その他

第5章 世界の低分子ヘパリン市場:包装別

  • イントロダクション
  • マルチバイアル
  • プレフィルドシリンジ

第6章 世界の低分子ヘパリン市場:用途別

  • イントロダクション
  • 深部静脈血栓症
  • 急性冠症候群(ACS)
  • 肺塞栓症
  • 心房細動

第7章 世界の低分子ヘパリン市場:エンドユーザー別

  • イントロダクション
  • 病院
    • 公的病院
    • 民間病院
  • 診療所
  • 在宅ケア

第8章 世界の低分子ヘパリン市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • フランス
    • スペイン
    • ロシア
    • その他
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • ASEAN
    • オーストラリア
    • 韓国
    • その他
  • 中南米
    • ブラジル
    • メキシコ
    • アルゼンチン
    • その他
  • アフリカ
    • 北アフリカ
    • 中央アフリカ
    • 南アフリカ
  • 中東
    • 湾岸協力会議(GCC)
    • イスラエル
    • その他

第9章 競争環境

  • ヒートマップ解析
  • 企業プロファイル
    • Pfizer, Inc.
    • LEO Pharma A/S
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.
    • Amphastar Pharmaceuticals Inc.
    • Aspen Pharmacare Holdings
    • Laboratorios Farmaceuticos ROVI SA
    • Changzhou Qianhong Biopharma
    • Intrapharm Laboratories
    • Abbott Laboratories

第10章 セクション

  • 参考文献
  • 調査方法
  • Coherent Market Insightsについて
目次

Low Molecular Weight Heparin (LMWH) has several advantages over other heparin such as longer and more predictable activity than Unfractionated Heparin (UFH) and can be self-administrated at home via subcutaneous injection, reducing or eliminating hospital stays, thereby no regular blood monitoring required. Furthermore, heparins do not cross the placenta or harm the fetus, so they are the preferred anticoagulants for pregnant women who experience or who are at heightened risk of - blood clots. These advantages make LMWH as the most preferred heparin in inhibiting clotting factors.

Market Dynamics

Increasing number of people are being affected with Deep Vein Thrombosis (DVT) which will subsequently increase demand for LMWH. For instance, according to National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC), February 2018; the precise number of people affected by DVT/PE is unknown, although as many as 900,000 people could be affected (1 to 2 per 1,000) each year in the U.S.

Furthermore, increasing engagement of government healthcare regulatory bodies in developing and delivering effective and cost-effective low molecular weight heparin molecule products in the market is expected to propel the growth of the market. For instance, in 2014, American Society of Health-System Pharmacists (ASHP) issued the policy for safe and effective use of heparin in neonatal patients thereby supporting the development and use of nationally standardized concentrations of heparin when used for maintenance and flush of peripheral and central venous lines in neonatal patients.

Key features of the study:

  • This report provides in-depth analysis of low molecular weight heparin market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 - 2026), considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, low molecular weight heparin approval & launch, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global low molecular weight heparin market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
  • Key companies covered as part of this study include, Pfizer, Inc., LEO Pharma A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, Changzhou Qianhong Biopharma, and Intrapharm Laboratories.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future drug launch, manufacturing up-gradation, market expansion, and marketing tactics
  • The global low molecular weight heparin market report caters to various stakeholders in this industry including investors, suppliers, low molecular weight heparin based product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the low molecular weight heparin market.

Detailed Segmentation:

  • Global Low Molecular Weight Heparin Market, By Drug:
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • Others
  • Global Low Molecular Weight Heparin Market, By Packaging:
  • Multi-vials
  • Prefilled Syringes
  • Global Low Molecular Weight Heparin Market, By Application:
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome (ACS)
  • Pulmonary Embolism
  • Atrial Fibrillation
  • Global Low Molecular Weight Heparin Market, By End Use:
  • Hospitals
    • Private
    • Public
  • Clinics
  • Home
  • Global Low Molecular Weight Heparin Market, By Geography:
  • North America
    • By Country:
  • U.S.
  • Canada
    • By Drug:
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • Others
    • By Packaging
  • Multi-vials
  • Prefilled Syringes
    • By Application:
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome (ACS)
  • Pulmonary Embolism
  • Atrial Fibrillation
    • By End Use:
  • Hospitals
  • Private
  • Public
  • Clinics
  • Home
  • Europe
    • By Country:
  • Germany
  • France
  • Italy
  • UK
  • Spain
  • Russia
  • Rest of Europe
    • By Drug:
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • Others
    • By Packaging
  • Multi-vials
  • Prefilled Syringes
    • By Application:
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome (ACS)
  • Pulmonary Embolism
  • Atrial Fibrillation
    • By End Use:
  • Hospitals
  • Private
  • Public
  • Clinics
  • Home
  • Asia Pacific
    • By Country:
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia Pacific
    • By Drug:
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • Others
    • By Packaging
  • Multi-vials
  • Prefilled Syringes
    • By Application:
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome (ACS)
  • Pulmonary Embolism
  • Atrial Fibrillation
    • By End Use:
  • Hospitals
  • Private
  • Public
  • Clinics
  • Home
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
    • By Drug:
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • Others
    • By Packaging
  • Multi-vials
  • Prefilled Syringes
    • By Application:
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome (ACS)
  • Pulmonary Embolism
  • Atrial Fibrillation
    • By End Use:
  • Hospitals
  • Private
  • Public
  • Clinics
  • Home
  • Latin America
    • By Country:
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
    • By Drug:
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • Others
    • By Packaging
  • Multi-vials
  • Prefilled Syringes
    • By Application:
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome (ACS)
  • Pulmonary Embolism
  • Atrial Fibrillation
    • By End Use:
  • Hospitals
  • Private
  • Public
  • Clinics
  • Home
  • Africa
    • By Country:
  • South Africa
  • Central Africa
  • North Africa
    • By Drug:
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • Others
    • By Packaging
  • Multi-vials
  • Prefilled Syringes
    • By Application:
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome (ACS)
  • Pulmonary Embolism
  • Atrial Fibrillation
    • By End Use:
  • Hospitals
  • Private
  • Public
  • Clinics
  • Home
  • Company Profiles
  • Pfizer, Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments
    • Strategies
  • LEO Pharma A/S
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Amphastar Pharmaceuticals Inc.
  • Abbott Laboratories
  • Aspen Pharmacare Holdings
  • Laboratorios Farmaceuticos ROVI SA
  • Changzhou Qianhong Biopharma
  • Intrapharm Laboratories

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug
    • Market Snippet, By Packaging
    • Market Snippet, By Application
    • Market Snippet, By End Use
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Epidemiology
  • Key Developments
  • Strategic Acquisitions
  • Advantages of LMWH over UFH
  • Cost-effectiveness of LMWH vs. UFH
  • Shortage of Enoxaparin & Estimated Resupply Dates
  • Drug Delivery Systems
  • Regulatory Scenario
  • Reimbursement Scenario
  • Buy-and-bill and White Bagging Channel
  • PEST Analysis

4. Global Low Molecular Weight Heparin Market, By Drug, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Enoxaparin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Dalteparin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Nadroparin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Bemiparin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Tinzaparin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

5. Global Low Molecular Weight Heparin Market, By Packaging, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Multi-vials
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Prefilled Syringes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

6. Global Low Molecular Weight Heparin Market, By Application, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Deep Vein Thrombosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Acute Coronary Syndrome (ACS)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Pulmonary Embolism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Atrial Fibrillation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

7. Global Low Molecular Weight Heparin Market, By End Use, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Private
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Public
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Home
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

8. Global Low Molecular Weight Heparin Market, By Region, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2026
  • North America
    • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • U.S.
  • Canada
  • Europe
    • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa
  • Middle East
    • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • GCC Countries
  • Israel
  • Rest of Middle East

9. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Pfizer, Inc.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • LEO Pharma A/S
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Sanofi S.A.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Amphastar Pharmaceuticals Inc.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Aspen Pharmacare Holdings
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Laboratorios Farmaceuticos ROVI SA
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Changzhou Qianhong Biopharma
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Intrapharm Laboratories
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Abbott Laboratories
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies

10. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top